【Abstract】 Refractory chronic spontaneous urticaria （CSU） is clinically common and poses significant diagnostic and therapeutic challenges due to resistance to standard or doubled doses of H1 antihistamines or their combination therapies. Current guidelines or consensus statements on urticaria have not met the needs for high-quality standardized management of refractory CSU, highlighting the necessity for specific guidelines for its diagnosis and treatment. Therefore, a guideline working group was established by the Chinese Society of Dermatology and the China Dermatologist Association, and consisted of 29 leading experts in urticaria research in China. Through a comprehensive review and evaluation of existing Chinese and international evidence-based data, and consideration of the situation in China, this guideline was formulated after multiple rounds of deliberation, aiming to provide guidance on the diagnosis and treatment of refractory CSU and to guide clinical practice.

【Abstract】 Vitiligo is a common autoimmune skin disease, currently believed to be caused by autoreactive T cell-mediated destruction of melanocytes in the skin, mucous membranes, or hair follicles, which can significantly induce psychological distress in patients. The consensus on the diagnosis and treatment of vitiligo （2024 version） was formulated by the Pigmentary Disorder Group, Combination of Traditional and Western Medicine Dermatology, etc., based on the latest international research progress in the diagnosis and treatment of vitiligo and actual situation in China. This version of consensus highlights early intervention, integrative therapy, application of JAK inhibitors in vitiligo, and provides future research directions, aiming to guide the treatment of vitiligo.

【Abstract】 Dermatitis and eczematous diseases are the most common group of diseases in dermatology. Currently, aside from atopic dermatitis, standardized clinical guidelines on the diagnosis and management of dermatitis and eczematous diseases remain lacking in China. Based on the “Expert consensus on standardized diagnostic terminology of dermatitis and eczematous diseases”, the Chinese Society of Dermatology and the China Dermatologist Association convened experts to develop the guidelines in accordance with the Delphi method. The guidelines address the clinical classification and characteristics of these conditions, diagnostic and therapeutic approaches to localized and generalized eczematous lesions, and principles of classified treatment, in order to further update the understanding of dermatitis and eczematous diseases and to provide guidance on standardized clinical diagnosis and treatment for dermatologists.

【Abstract】 Acne vulgaris （abbreviated as acne） is a common aesthetic-impairing dermatological disease that markedly affects appearance, and is characterized by diverse clinical manifestations. At present, there are various grading systems for acne severity, while there is still a lack of unified standards for objectively assessing disease severity to guide treatment selection and scientifically evaluating the efficacy of acne therapies, which are also highly concerned issues for clinicians. To address this, the Acne Study Group of China Dermatologist Association, the Dermatology Professional Committee of Chinese Research Hospital Association, and the Acne Study Group of Dermatology and Venereology Professional Committee of Chinese Association of Integrative Medicine organized a group of experts in the field of acne diagnosis and treatment in China to develop the "Chinese expert consensus on clinical severity grading and therapeutic evaluation of acne vulgaris" after extensive discussions, aiming to provide a reference for dermatologists in clinical practice.

【Abstract】 To enhance clinicians′ understanding of pigmented nevi and standardize their diagnosis and treatment, a group of experts from the Skin Cancer Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, the Melanoma Society of China Anti-Cancer Association and the Society of Integrated Rehabilitation of Skin Tumors, China Anti-Cancer Association, adhering to the principles of evidence-based medicine, integrated the latest Chinese and international guidelines, consensuses, and existing research findings to formulate the expert consensus on diagnosis and treatment of pigmented nevi （2025 edition） through two rounds of intensive revisions and discussions. This consensus covers various types of pigmented nevi, including common acquired pigmented nevi, congenital pigmented nevi, recurrent pigmented nevi, and pigmented nevi in special populations （children, pregnant women）, and offers detailed recommendations on the key points for the diagnosis and treatment of these types of pigmented nevi, aiming to provide a reference for the standardized diagnosis, treatment, and management of pigmented nevi.

【Abstract】 Topical medications form the cornerstone of atopic dermatitis （AD） treatment, and their standardized application is crucial for optimizing therapeutic efficacy and reducing the incidence of adverse reactions. Developed by a multidisciplinary expert team, this consensus is meticulously crafted based on evidence-based medicine for AD, Chinese and international guidelines, and expert clinical experience, and is closely tailored to the disease characteristics of Chinese AD patients. The consensus systematically outlines the application principles of classic and emerging topical agents, emphasizes strategies of stepwise therapy and proactive maintenance treatment, and establishes specific medication protocols for special anatomical sites and vulnerable populations. Aiming to provide clinicians with systematic, scientific, and standardized medication guidance, this consensus seeks to enhance the overall management of AD.

【Abstract】 Bullous pemphigoid （BP） is an autoimmune subepidermal blistering skin disease that primarily affects the elderly. Clinically, it is characterized by tense blisters and bullae on the local or whole body skin, which can be life-threatening in some patients. The pathogenesis of BP is closely related to anti-BP180 and anti-BP230 antibodies, which cause BP through pathways such as complement activation systems and non-complement systems. This consensus covers clinical characteristics, diagnostic criteria, treatment options, and management of comorbidities associated with BP, with a particular emphasis on the importance of individualized treatment. In terms of diagnosis, a comprehensive approach integrating clinical manifestations, histopathological features, direct immunofluorescence and serological testing results is proposed to improve diagnostic accuracy. In terms of treatment, in addition to traditional glucocorticoids and immunosuppressive agents, new drugs such as biological agents are also recommended, and individualized treatment regimens are formulated according to the disease severity. Additionally, the consensus also pays attention to the management of BP-related comorbidities such as diabetes, kidney disease, and malignant tumors, providing comprehensive guidance for clinicians to improve the treatment outcomes and quality of life of BP patients.

【Abstract】 Ultraviolet phototherapy stands as a pivotal intervention in the management of vitiligo. To guide and standardize the application of ultraviolet phototherapy in the treatment of vitiligo, and to improve its efficacy and safety, the Dermatology Professional Committee of Chinese Research Hospital Society and the China Dermatologist Association organized Chinese experts in the fields of photomedicine and pigmentary disorders to formulate the “Guideline on phototherapy for vitiligo （2025 edition）” after thorough discussions based on the latest research progress in vitiligo phototherapy in China and other countries in recent years and the clinical experience of experts. This guideline comprehensively delineates core clinical considerations pertaining to phototherapy for vitiligo, including the therapeutic principles, contraindications, individualized phototherapy protocols, strategies for combination therapies, and management of adverse reactions, aiming to further improve the performance of phototherapy in the treatment of vitiligo in China.

【Abstract】 Red, blue, and yellow light therapy is a type of low-level light therapy commonly used in clinical practice. In recent years, with the development of photomedicine technology, safer and more effective red, blue, and yellow light therapy has been promoted and applied in the treatment of acne, androgenetic alopecia, skin wounds, herpes zoster, and other skin diseases. However, there is no unified standardized treatment protocol. In order to improve the efficacy and safety of the red, blue, and yellow light therapy, the Chinese Association of Rehabilitation Dermatology, the Chinese Society of Dermatology, and the Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment organized some experts to formulate the consensus based on Chinese and international literature and clinical guidelines, as well as the current clinical practice in China, aiming to propose specific recommendations for the standardized application of red, blue, and yellow light therapy in dermatology, and provide a reference for clinicians.

【Abstract】 In recent years, research on pruritus in the elderly has progressed rapidly, deepening the understanding of this condition. In order to standardize the diagnosis, treatment and rehabilitation of pruritus in the elderly, experts from the Chinese Association Rehabilitation of Dermatology, and the Working Group on Geriatric Dermatology, Combination of Traditional and Western Medicine Dermatology organized relevant experts and formulated an expert consensus on the diagnosis, treatment, and rehabilitation of pruritus in the elderly （2025 edition） based on the latest Chinese and international research advancements, with a particular focus on evidence-based medicine. This consensus aims to provide recommendations to address clinical problems, alleviate or eliminate patients′ symptoms and improve their quality of life.

【Abstract】 With the progress in dermatology in recent decades, some new biologic agents and small-molecule targeted drugs have been approved for the treatment of skin diseases, and have showed favorable therapeutic effect, especially in the treatment of complex and refractory dermatoses. However, how to apply targeted therapy reasonably, effectively and safely in the treatment of skin diseases has become a matter of great concern in clinical practice. To this end, the Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment organized relevant experts to formulate this consensus through multiple in-depth discussions and revisions based on Chinese and international research data, clinical guidelines and consensus, as well as characteristics of Chinese patients. According to the classification of diseases, specific guidance was provided in this consensus for clinicians regarding the clinical application principles and treatment protocols of biologic agents and small-molecule targeted drugs.

【Abstract】 Localized scleroderma （LS） is a rare skin disorder characterized by fibrosis in the dermis and subcutaneous tissues. In severe cases, it can affect patients′ appearance, physical function, and quality of life. Currently, there is a lack of Chinese guidelines or consensus on the diagnosis and treatment of LS, leading to variability in clinical practice. To enhance dermatologists′ understanding of LS and standardize its diagnosis and management, the Chinese Society of Dermatology and the China Dermatologist Association organized a panel of leading experts in the field of dermatology to develop a consensus through systematic literature review and integration of recent Chinese and international research advances. The consensus comprehensively summarized the clinical subtypes, diagnostic criteria, differential diagnoses, and assessment methods of LS, as well as treatment strategies for LS, aiming to provide evidence-based guidance for standardizing the clinical management of LS in China.

【Abstract】 Port-wine stain （PWS） is the most common type of low-flow capillary malformations in children. PWS often occurs after birth with a predilection for the face and neck, seriously affecting the physical and mental health of patients and the quality of life of their families. Compared with adults, children are in a growth and development stage. PWS-related syndromes can affect extracutaneous organs, but may only present with mild erythema in the early stage, and is liable to result in misdiagnosis or missed diagnosis. Therefore, early recognition is particularly important. Based on the latest Chinese and international research progress and through extensive discussions, the Consensus Development Expert Group on Diagnosis and Treatment of PWS in Chinese Children formulated the consensus on the etiology, pathogenesis, clinical manifestations, laboratory examinations, diagnosis, differential diagnosis, and treatment of, as well as health education for PWS in children, aiming to provide guidance for clinicians on the diagnosis and treatment of PWS.

【Abstract】 Cancer treatment-related cutaneous adverse events （TRCAEs） are critical issues that significantly affect patients′ quality of life and treatment adherence. Approximately two-thirds of cancer patients develop at least one type of TRCAE within 3 months of therapy, and about one-third discontinue treatment as a result. In response, experts from the Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment, the Patient Education Expert Committee, Chinese Society of Clinical Oncology, and other related fields jointly developed the “Chinese expert consensus on multidisciplinary management of cancer treatment-related cutaneous adverse events （2026 edition）”. This consensus pioneers a multidisciplinary team framework integrating oncology, dermatology, nursing, and pharmacy. It establishes standardized tiered interventions and evidence-based management strategies for 7 major categories of TRCAEs, encompassing prevention, basic care, pharmacotherapy, and traditional Chinese medicine. Special attention is given to individualized treatment adjustments and nursing guidance for specific patient populations. Furthermore, the consensus emphasizes the importance of patient education and explores the adjunctive application of dermocosmetics. This consensus aims to offer evidence-based, standardized guidance for clinical practice, thereby helping to improve patient outcomes and quality of life.

【Abstract】 Atopic dermatitis （AD） is a chronic inflammatory skin disease. In recent years, with the development and application of targeted drugs, the treatment of AD is entering the era of individualization. Stratification of patients based on different dimensions can help realize individualized treatment, but currently there is a lack of stratification strategies for individualized treatment of AD. Therefore, the consensus on stratified individualized systemic treatment for moderate to severe AD was formulated by experts from the Immunology Group, Chinese Society of Dermatology and the Dermatology Professional Committee of Chinese Research Hospital Society, based on the latest research progress in AD in China and other countries as well as experts′ clinical practice experience. The consensus encompasses the individualized comprehensive assessment, systemic therapeutic drugs, selection of therapeutic options according to different dimensions, and the mode of systemic treatment of AD, aiming to guide clinical individualized medication.

【Abstract】 Rosacea is a kind of recurrent inflammatory skin disease that predominantly occurs on the face, significantly impacting the physical and mental health of patients. Properly guiding patients to understand rosacea, avoid potential triggers, and receive standardized treatment and skincare are important measures for effectively controlling the condition and preventing disease recurrence. Therefore, how to guide clinicians to provide patient education in a scientific, rational, and standardized way is particularly important. In order to enhance the awareness among Chinese clinicians regarding the importance of patient education for rosacea and to form unified and standardized guidance principles, the Chinese Society of Dermatology, the China Dermatologist Association, the Combination of Traditional and Western Medicine Dermatology, and the Chinese Non-Government Dermatologist Institutions Association organized Chinese experts focused on rosacea to develop a consensus based on the current status and advances in Chinese and international research. This consensus provides guidance on how clinicians can guide patients to correctly understand the disease, identify and reasonably avoid various triggers, receive standardized pharmacotherapy and laser/light therapies, and address psychological states and comorbidities. Additionally, expert recommendations were formulated through the Delphi method for clinical reference.

【Abstract】 Pemphigus is an autoimmune bullous disease, and paraneoplastic pemphigus （PNP） is a unique subtype of pemphigus. Clinical characteristics of PNP mainly include severe and refractory painful erosions and ulcers of the mucosa, polymorphous skin lesions, and comorbid neoplasms, often accompanied by other systemic involvement （such as bronchiolitis obliterans）. Most patients respond poorly to treatment, and in severe cases, it is life-threatening. The diagnosis and treatment of PNP involves dermatology, stomatology, oncology, hematology, respiratory medicine, surgery, anesthesiology, general internal medicine, intensive care unit and other departments. Relevant academic organizations enrolled experts in related fields together to formulate this consensus, to provide guidance for the diagnosis and treatment of PNP. Chinese standards for PNP diagnosis are proposed based on the status of diagnosis and treatment of PNP in China. Treatment suggestions are put forward from the aspects of skin and mucosal involvement, neoplasms, bronchiolitis obliterans, and complications.

【Abstract】 Seborrheic dermatitis is a chronic, recurrent, and inflammatory skin disease. Its etiology is intricately related to skin microecological imbalance, dysregulated lipid metabolism, impaired skin barrier function, abnormal immune responses, and genetic predispositions. In recent years, several novel therapeutic approaches have emerged, such as topical phosphodiesterase 4 inhibitors, Janus kinase inhibitors, physical interventions, and chemical peeling, providing more options for the treatment of seborrheic dermatitis. This review summarizes the latest research progress in the pathogenesis and treatment of seborrheic dermatitis.

【Abstract】 Atopic dermatitis （AD） is the most common chronic inflammatory disease in dermatology, often beginning in infancy. It can recur and persist into childhood and adolescence, severely affecting sleep, growth and development of children, impairing the quality of life of both the children and their families, and imposing significant social and economic burden. In recent years, the prevalence of AD among children in China has been rising. However, the diagnosis and treatment vary widely across different regions and medical institutions. Meanwhile, there is a lack of evidence?based medicine specific to Chinese children with AD in real?world settings, and the concepts and measures for chronic disease management of AD have not been widely established. To promote the establishment of specialized AD clinics in pediatric dermatology in China, enhance clinical diagnosis and treatment, standardize treatment processes, reduce the disease burden, and improve the quality of life of children and their families, the Group on Children, Chinese Society of Dermatology, the Dermatology and Venereology Group, Chinese Pediatric Society, Chinese Medical Association, the Chinese Association of Rehabilitation Dermatology, and the Pediatric Dermatology Group, China Dermatologist Association organized domestic experts for extensive surveys and discussions. Combining international guidelines with the situation in China, this consensus was formed to provide a reference for the construction of specialized AD clinics in pediatric dermatology in China, and enhance the capability to provide comprehensive care for children with AD throughout the entire disease course.

【Abstract】 Psoriasis is an immune-mediated, chronic, inflammatory and systemic disease that can occur at any age and has a profound impact on patients′ quality of life. Interleukin-17A is a key pro-inflammatory cytokine involved in the pathogenesis of psoriasis. Secukinumab is a fully human anti-interleukin-17A monoclonal antibody. It is approved in China for the treatment of moderate‐to‐severe plaque psoriasis in patients aged 6 years or older, active psoriatic arthritis in adults and ankylosing spondylitis in adults. Since its launch, a large amount of real‐world data on the efficacy and safety has been accumulated in China. To standardize the use of secukinumab in the long‐term management of psoriasis, a systematic review of the literature on the long-term efficacy and safety of secukinumab as well as its treatment strategies and use in special populations was conducted, and an expert consensus was proposed.

【Abstract】 Pyoderma gangrenosum （PG） is a rare neutrophilic dermatosis. Its most common clinical manifestation is the occult development of ulcers in normal or traumatized skin. PG is often associated with other systemic diseases. Early diagnosis and standardized treatment are crucial for managing PG and its associated comorbidities. Currently, there are no relevant diagnostic and therapeutic guidelines or consensus in China. Based on the latest Chinese and international research progress and international guidelines, the Chinese Society of Dermatology and the China Dermatologist Association organized experts in the relevant fields to develop this consensus using the Grading of Recommendations, Assessment, Development, and Evaluation （GRADE） approach and the Delphi method. This consensus focuses on the diagnostic criteria, severity assessment, and treatment strategies for PG, with the aim of providing guidance on the diagnosis, treatment, and long-term management of PG in China.

cover and contents

【Abstract】 Topical minoxidil has been applied to the treatment of androgenetic alopecia （AGA） in clinical practice for a long time, but some problems still exist, such as unsatisfactory efficacy or poor tolerance. Currently, oral minoxidil is only indicated as second- or third-line therapy for hypertension, but growing evidence has supported the off-label use of low-dose oral minoxidil for the treatment of AGA. This review summarizes possible mechanisms and clinical application of low-dose oral minoxidil in the treatment of AGA.

【Abstract】 Scabies is a common infectious dermatosis caused by Sarcoptes scabiei var. hominis, and mainly transmitted by direct skin contact. It occurs predominantly in children and the elderly. Clinically, it is divided into common scabies, crusted scabies, nodular scabies, bullous scabies, and nail scabies. Detection of scabies mites, eggs and fecal pellets on skin scraping is still the gold standard for the diagnosis of scabies, but several non-invasive techniques, such as dermoscopy, have become common methods. On dermoscopy, a dark-brown triangular structure （representing the anterior part of the mite） with its linear burrows, known as the “jet with contrail sign”, is pathognomonic for scabies. In 2020, the International Alliance for the Control of Scabies recommended three levels （confirmed scabies, clinical scabies and suspected scabies） of diagnostic certainty. Common scabies is usually treated with topical scabicides, of which permethrin is the first-line treatment, and benzyl benzoate and sulfur are the second line choice. A combined regimen of oral ivermectin with topical permethrin and keratolytics is the first-line therapy for crusted scabies.

【Abstract】 Currently, topical glucocorticoids are still the first-line treatment of chronic hand eczema, while systematic treatment is required for moderate to severe chronic hand eczema with no response to topical corticosteroids. Traditional treatments include glucocorticoids, antihistamines, retinoids, immunosuppressants, etc. In recent years, some progress has been made in the treatment of chronic hand eczema with Janus kinase inhibitors, phosphodiesterase 4 inhibitors, biological agents, statins, timolol, daylight photodynamic therapy, etc. This review summarizes recent advances in the treatment of chronic hand eczema, including basic therapy, topical treatment, physical therapy and systemic therapy.

【Abstract】 Psoriasis is a chronic, recurrent, inflammatory systemic disease that often coexists with various comorbidities, such as metabolic syndrome, cardiovascular diseases, diabetes, and psychiatric disorders, significantly impacting patients' physical and mental health. Proactively managing psoriasis comorbidities is of great importance for standardizing diagnostic and treatment pathways and improving clinical outcomes. Based on previous Chinese and international guidelines, clinical consensus, and the latest research advancements, this consensus systematically summarizes the management strategies for psoriasis with comorbidities, provides an in-depth elucidation of the treatment, prevention, and rehabilitation of psoriasis comorbidities, aiming to offer a scientific reference to healthcare professionals involved in psoriasis diagnosis and treatment in China.

【Abstract】 Cholinergic urticaria （CholU） is a special type of chronic inducible urticaria characterized by transient, needle-sized wheals and erythema with stinging pain and/or itching, precipitated by increased core body temperature as a result of exercise or passive heating. Some cases were accompanied by angioedema, which seriously affects their quality of life. The pathogenesis of CholU involves sweat allergy and atopic diathesis, increased histamine release in sweat and the influence of Malassezia, decreased cholinergic receptors in hypohidrotic areas, decreased expression of cholinesterase, serum factors and autoantibodies, etc. Standard-dose and updosed second generation H1-antihistamines are the first-line therapy for CholU. For refractory CholU patients with normal sweating, biological agents, sweat desensitization and other therapies could be further chosen, while patients with severe hypohidrosis could be further treated with glucocorticoid pulse therapy and so on. This review summarizes the pathogenesis, classification, clinical manifestations, diagnosis and treatment of CholU from the perspective of the role of sweat in the pathogenesis of CholU.

【Abstract】 Apremilast is the first oral targeted small-molecule drug approved for the treatment of psoriasis in China. Due to mechanisms underlying the specific regulatory effect of apremilast on the balance of inflammation via targeting phosphodiesterase 4, it has been widely used for the treatment of various types of psoriasis. Many studies have confirmed that apremilast is effective in the treatment of mild to severe plaque psoriasis, psoriasis in special areas, psoriatic arthritis, palmoplantar pustulosis, and pediatric psoriasis, with good safety and tolerability profiles. Based on the pharmacological mechanisms of apremilast and clinical data on the treatment of psoriasis, the Committee on Psoriasis, Chinese Society of Dermatology convened relevant experts to develop this proposal to ensure the standardized, reasonable, safe and effective use of apremilast in the treatment of psoriasis.

【Abstract】 Atopic dermatitis （AD） is a common chronic, recurrent, inflammatory, and pruritic skin disease in children. It not only affects sleep quality, growth and development, learning efficiency, social functioning, and mental health, but also significantly reduces the quality of life of affected children and their families, and increases multidimensional medical, social, and economic burdens. In recent years, research into the pathogenesis of AD has advanced substantially, demonstrating that epidermal barrier dysfunction, aberrant type 2 immune responses, microbial dysbiosis, and genetic susceptibility jointly contribute to disease onset and progression. The emergence of biologics and small-molecule targeted therapies has marked the entry of AD treatment into the era of precision medicine, while the concepts in disease management have shifted from “symptom control” to “whole-process management and disease modification”. Meanwhile, progress has been achieved in early prediction and prevention strategies for AD, and “early prevention, precision treatment, and whole-process management” are considered the core principles of effective disease control. This consensus adopts “prediction and prevention-stepwise treatment-comorbidity management-whole-process management” as its core framework, with a focus on key dimensions including tertiary prevention strategies, stratified and individualized treatment approaches, identification and management of common complications and comorbidities, as well as patient education and long-term management. It aims to provide a scientific, standardized, and practical reference for the integrated clinical practice of “prevention-treatment-management” for childhood AD in China, thereby improving prevention and treatment outcomes, enhancing long-term prognosis, improving the quality of life of affected children and their families, and effectively reducing the overall disease burden.

【Abstract】 Objective To investigate the clinical efficacy of autologous adipose-derived stem cell gel （SVF-gel） grafting in the treatment of depressed acne scars. Methods A retrospective analysis was conducted on data collected from 28 patients who underwent SVF-gel grafting treatment for depressed acne scars in the Department of Dermatology, Xijing Hospital, Air Force Medical University from October 2018 to May 2021. There were 17 males and 11 females, aged 17 - 38 （26 ± 4.86） years. As for clinical types, 8 patients were diagnosed with boxcar acne scars, 14 with rolling acne scars, and 6 with acne scars with characteristics of the two types. The clinical acne scar weighted scale （ECCA scale） was used to evaluate the appearance improvement after the treatment, and patients′ subjective satisfaction scores and incidence of adverse reactions were recorded. Results After the SVF-gel grafting, the facial appearance of patients with depressed acne scars significantly improved, and the ECCA scores significantly decreased 6 months after surgery （before surgery: 52.5 ± 15.8 points; 6 months after surgery: 23.8 ± 10.2 points; t = 11.68, P < 0.001）. The subjective satisfaction rate of patients was 82.14% （23/28）, the incidence rate of adverse reactions was 17.86% （5/28）, and 5 patients experienced mild inflammatory reactions after surgery, including 2 with subcutaneous nodules. The secondary grafting rate was 67.86% （19/28）. Conclusion The SVF-gel grafting was markedly effective for the treatment of depressed acne scars, which is worthy of clinical promotion and application.

【Abstract】 In order to further promote the construction of outpatient departments for treat-to-target of atopic dermatitis （AD） by combining with the clinical reality of primary hospitals, implementing the treat-to-target concept of AD, standardizing the setting and operation of treat-to-target outpatient departments of AD, and improving the ability of primary medical services, the Chinese Society of Dermatology and the China Dermatologist Association established the expert committee on outpatient department construction for treat-to-target of AD, and formed the construction standards for primary hospitals in China based on “Construction of treat-to-target outpatient department of atopic dermatitis in China （2023）”. This standard puts forward the management requirements and scoring criteria for treat-to-target outpatient departments of AD to primary care dermatology, which is conducive to improving the standardized diagnosis and treatment of AD and making further efforts to facilitate the homogenization of AD management and rationalization of medical resource allocation.

【Abstract】 Objective To detect pathogenic gene mutations in a patient with CARD14-associated papulosquamous eruption （CAPE） and his family, and to observe the short-term and long-term efficacy and safety of ustekinumab treatment. Methods Clinical data were collected from a 6-year-old child presenting with erythroderma secondary to pityriasis rubra pilaris and his family members. Peripheral blood samples were collected from the patient, his parents and younger brother, and DNA was extracted from these peripheral blood samples. A next-generation skin-targeted sequencing panel was used to detect gene mutations, and Sanger sequencing was performed for verification. Genomic DNA was also extracted from 100 unrelated healthy controls using the same method. Results A heterozygous mutation c.349+1G>A in intron 6 of the CARD14 gene was identified in the proband and his mother, but was not identified in his father, younger brother or 100 healthy controls, leading to a diagnosis of CAPE in the proband. The patient received subcutaneous injections of ustekinumab at a dose of 45 mg at weeks 0 and 4, and every 12 weeks thereafter. After 1-week treatment, the skin lesions and symptoms improved markedly. No adverse events were reported during the 18-month treatment and follow-up. Conclusion The heterozygous mutation c.349+1G>A in the CARD14 gene may be the cause of the disease in this family, and ustekinumab was effective and safe for the treatment of CAPE.

【Abstract】 Moisturizer therapy is one of the fundamental treatments for atopic dermatitis. However, many challenges still exist in clinical practice despite its wide application. Based on Chinese and international guidelines, consensus, and clinical literature, and combined with expert clinical experience, an expert consensus on the rational use of moisturizers for atopic dermatitis was developed by a panel of Chinese experts convened by the Environmental and Occupational Skin Disease Research Group, Chinese Dermatovenerology Society of Integrative Medicine and other academic institutions. This consensus addresses key issues regarding the use of moisturizers in the management of atopic dermatitis, including the necessity of use, mechanisms of action, indications, contraindications, considerations during the application, selection principles, usage, dosage, and adverse reactions, aiming to provide guidance for the standardized application of moisturizers in clinical practice.

【Abstract】 Alopecia areata is a T cell-mediated autoimmune non-scarring hair loss disorder. Its core pathogenesis involves the collapse of immune privilege in hair follicles, which subsequently triggers CD8? T cell-mediated autoimmune responses and activates multiple inflammatory pathways, including Th1, Th2, Th17, and Treg pathways. Genetic susceptibility also contributes to disease development. Pediatric alopecia areata is highly heterogeneous. Earlier age at onset, particularly before 6 years of age, is associated with greater disease severity and higher recurrence rates, leading to a more substantial impact on the quality of life of affected children and their families. Pediatric alopecia areata should be differentiated from congenital and other acquired hair loss disorders in children. Currently, the management of pediatric alopecia areata faces challenges such as age restrictions for certain treatments and limited high-level evidence-based medical data. Therefore, stratified management based on age, disease stage, and severity is recommended. Based on the latest Chinese and international clinical guidelines and research evidence, as well as key clinical questions identified using the Delphi method, an expert panel was organized to develop this consensus after systematic evaluation and discussion. This consensus provides recommendations covering clinical classification, diagnostic pathways, assessment tools, and treatment strategies, aiming to promote the standardized diagnosis and treatment of pediatric alopecia areata in China and provide guidance for clinical practice.

【Abstract】 Hereditary angioedema （HAE） is a rare autosomal dominant hereditary disorder mediated by bradykinin and characterized by recurrent skin and/or mucosal edema. HAE attacks commonly affect the skin, upper respiratory tract and gastrointestinal tract. Laryngeal edema in HAE patients carries a high mortality rate. Enhancing dermatologists′ ability to diagnose and treat HAE can significantly improve patient outcomes. This consensus was developed based on Chinese and international high-quality literature in recent years and clinical experience of 19 dermatological experts in China, aiming to provide standardized diagnosis and treatment pathway for HAE.

【Abstract】 Lichen planopilaris （LPP） and frontal fibrosing alopecia （FFA） are the two most common types of primary lymphocytic cicatricial alopecia in clinical practice, but their treatment poses significant challenges. These conditions are characterized by the replacement of hair follicle-sebaceous gland units with fibrous tissues, leading to irreversible destruction of hair follicles and ultimately resulting in scarring of the follicles. In recent years, with a deepened understanding of these two diseases, new treatment options have emerged in addition to traditional topical medications and systemic oral drugs, including novel topical small molecule drugs such as Janus kinase inhibitors. Based on the latest Chinese and international consensus as well as current clinical practice in China, the Hair Research Group of Chinese Society of Dermatology organized experts to develop a consensus on the etiology, pathogenesis, clinical manifestations, auxiliary examinations, diagnosis, differential diagnosis, and treatment of LPP and FFA after thorough discussions, aiming to further standardize the clinical diagnosis and treatment of these two conditions and provide a more scientific and authoritative reference.

【Abstract】 Uncommon types of dermatophytoses have garnered increasing clinical attention. These conditions primarily include dermatophyte infections occurring in special populations （such as tinea capitis in adults, infants, and young children, as well as onychomycosis in minors）, infections involving special anatomical sites （such as tinea of vellus hair and genital dermatophytoses）, infections caused by uncommon or drug-resistant dermatophytes （e.g., Trichophyton indotineae）, and deep dermatophytoses associated with host immunocompromise or trauma （such as Majocchi′s granuloma, dermatophyte pseudomycetoma, and deep or disseminated dermatophytoses）. Clinically, these uncommon dermatophytoses often exhibit distinct characteristics in epidemiology, clinical manifestations, diagnosis, and treatment, are prone to misdiagnosis or delayed diagnosis, and remain treatment challenges due to the absence of standardized diagnostic and therapeutic protocols. To address these gaps, the Mycology Group of Chinese Dermatovenerology Society of Integrative Medicine and the Infection Group of Chinese Preventive Medicine Association Professional Committee on Prevention and Control of Dermatology and Sexually Transmitted Diseases convened a panel of experts to develop this expert consensus to address key issues regarding the epidemiology, clinical features, diagnosis, and treatment of these uncommon types of dermatophytoses, aiming to provide scientific and standardized guidance for clinical practice.

【Abstract】 The interleukin-36 pathway plays an important role in the pathogenesis of various inflammatory skin diseases, including generalized pustular psoriasis （GPP）. Anti-interleukin-36R monoclonal antibodies, represented by spesolimab, provide more therapeutic options for GPP and other inflammatory skin diseases. The Chinese Society of Dermatology, the China Dermatologist Association, and other institutions convened experts in the relevant field to develop this consensus to provide recommendations on the indications, treatment regimens, and safety management of spesolimab in inflammatory skin diseases, such as GPP, localized pustular psoriasis, hidradenitis suppurativa, pyoderma gangrenosum, acute febrile neutrophilic dermatosis, and acute generalized exanthematous pustulosis, with the aim of guiding its clinical application. The application of spesolimab in special populations such as pediatric, pregnant, and elderly patients requires further clinical evidence. Future studies should focus on the long-term efficacy and safety of spesolimab in the treatment of GPP, and explore its potential in treating inflammatory skin diseases, particularly refractory neutrophilic dermatoses.

【Abstract】 Syphilis, gonorrhea, and genital herpes are major sexually transmitted diseases （STDs） that require prioritized prevention and control in China. Syphilis has complex clinical manifestations and is classified as primary syphilis, secondary syphilis, tertiary syphilis, neurosyphilis, latent syphilis and congenital syphilis, etc. Gonorrhea mainly affects the urogenital tract, and its clinical manifestations markedly vary from asymptomatic types to complicated types. Genital herpes is a chronic and recurrent STD. The diagnosis of these three STDs should be established by integrating epidemiological history, clinical features, and laboratory findings. Upon diagnosis, treatment should be initiated as early as possible according to recommended regimens, and appropriate follow-up should be performed after treatment. In recent years, the evolving epidemic trends of STDs and advances in diagnostic and therapeutic techniques have deepened the understanding of their transmission, pathogenesis, diagnosis and treatment. To enhance their prevention and control, the National Center for STD Control of the Chinese Center for Disease Control and Prevention, the Venereology Group of the Chinese Society of Dermatology, and the Subcommittee on Venereology of the China Dermatologist Association convened experts to formulate the "Guidelines for diagnosis and treatment of syphilis, gonorrhea, and genital herpes （2026 edition）".

【Abstract】 Objective To retrospectively analyze the clinical efficacy and safety of biological agents in the treatment of psoriasis in the elderly. Methods A retrospective study was conducted. A total of 124 patients aged ≥ 65 years with moderate-to-severe psoriasis （psoriasis area and severity index ［PASI］ score ≥ 3 points or body surface area ［BSA］ ≥ 3%）, who were treated with biological agents at the Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, from June 2020 to December 2023, were collected. PASI, BSA, and dermatology life quality index （DLQI） scores were recorded at weeks 0 （pre-treatment）, 4, 12, and 24 after the beginning of treatment to evaluate the efficacy. The proportions of patients achieving ≥ 75% and 90% improvements in PASI scores （PASI75 and PASI90, respectively） were calculated, and adverse reactions were recorded. Data were processed using SPSS 29.0 and GraphPad Prism 10.0 software. Normally distributed continuous variables were presented as mean ± standard deviation, while non-normally distributed continuous variables were presented as median with upper and lower quartiles （Q1, Q3）. Wilcoxon signed-rank test was used for comparisons of non-normally distributed data between groups, and chi-square test and Fisher's exact test were used for comparing categorical data. Results Among the 124 patients, there were 72 males （58.1%） and 52 females （41.9%）, and their ages ranged from 65 to 87 years. Treatment regimens included secukinumab for 86 patients （69.4%）, ustekinumab for 15 （12.1%）, ixekizumab for 14 （11.3%）, guselkumab for 5 （4.0%）, and adalimumab for 4 patients （3.2%）. The pre-treatment PASI, BSA, and DLQI scores ［M （Q1 , Q3）］ were 12.2 （7.8, 19.6） points, 16.0% （10.2%, 25.0%）, and 16 （11, 20） points respectively, which significantly decreased to 0.8 （0, 1.2） points, 1.0% （0, 2.0%）, and 0 （0, 3） points respectively at week 24 after the start of treatment （Z = 9.66, 9.66, 9.63, respectively, all P < 0.01）. The proportions of patients achieving PASI75 at weeks 4, 12, and 24 were 42.7%（53/124）, 80.6%（100/124）, and 93.5%（116/124） respectively, and those achieving PASI90 were 13.7%（17/124）, 48.4%（60/124）, and 85.5%（106/124） respectively. There were no significant differences in the proportions of patients achieving PASI75 and PASI90 between the subgroups with and without comorbidities, as well as between the early-onset psoriasis subgroup and late-onset psoriasis subgroup at weeks 4, 12, and 24 （all P > 0.05）. Among the 124 patients, 42 were followed up for over 2 years, and the proportions of patients achieving PASI75 and PASI90 after 2 years of treatment were 71.4% （30 cases） and 54.8% （23 cases）, respectively. Adverse reactions occurred in 13 patients, including upper respiratory infections in 4 patients （3.2%）, elevated aminotransferase levels in 3 patients （2.4%）, eczematoid dermatitis in 2 patients （1.6%）, pruritus in 2 patients （1.6%）, nodular prurigo in 1 patient （0.1%）, and vitiligo in 1 patient （0.1%）. Conclusion Biological agents showed rapid and marked efficacy in the treatment of moderate-to-severe psoriasis in the elderly, with few and mild adverse reactions, suggesting high safety and overall marked efficacy.